Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis.
Ascites
CSPH, clinically significant portal hypertension
Ct, cycle threshold
HVPG, hepatic venous pressure gradient
NSBBs, non-selective beta-blockers
ROC, receiver-operating characteristic
beta-blockers
cirrhosis
miRNAs, microRNAs
microRNA
portal hypertension
Journal
JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
05
07
2021
revised:
19
08
2021
accepted:
08
09
2021
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
30
10
2021
Statut:
epublish
Résumé
Treatment with non-selective beta-blockers (NSBBs) reduces the risk of ascites, which is the most common decompensating event in cirrhosis. This study aimed to assess the ability of a serum microRNA (miRNA) signature to predict ascites formation and the hemodynamic response to NSBBs in compensated cirrhosis. Serum levels of miR-452-5p, miR-429, miR-885-5p, miR-181b-5p, and miR-122-5p were analyzed in patients with compensated cirrhosis (N = 105). Hepatic venous pressure gradient (HVPG) was measured at baseline, after intravenous propranolol, and 1 year after randomization to NSBBs (n = 52) or placebo (n = 53) (PREDESCI trial). miRNAs were analyzed at baseline and at 1 year. Nineteen patients (18%) developed ascites, of whom 17 developed ascites after 1 year. miR-181b-5p levels at 1 year, but not at baseline, were higher in patients that developed ascites. The AUC of miR-181b-5p at 1 year to predict ascites was 0.7 (95% CI 0.59-0.78). miR-429 levels were lower at baseline in acute HVPG responders to NSBBs (AUC 0.65; 95% CI, 0.53-0.76), but levels at baseline and at 1 year were not associated with the HVPG response to NSBBs at 1 year. Serum miR-181b-5p is a promising non-invasive biomarker to identify patients with compensated cirrhosis at risk of ascites development. Ascites marks the transition from the compensated to decompensated stage in cirrhosis and indicates a worsening in prognosis. There are currently no easily accessible tools to identify patients with compensated cirrhosis at risk of developing ascites. We evaluated the levels of novel molecules termed microRNAs in the blood of patients with compensated cirrhosis and observed that miR-181b-5p can predict which patients are going to develop ascites.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
Treatment with non-selective beta-blockers (NSBBs) reduces the risk of ascites, which is the most common decompensating event in cirrhosis. This study aimed to assess the ability of a serum microRNA (miRNA) signature to predict ascites formation and the hemodynamic response to NSBBs in compensated cirrhosis.
METHODS
METHODS
Serum levels of miR-452-5p, miR-429, miR-885-5p, miR-181b-5p, and miR-122-5p were analyzed in patients with compensated cirrhosis (N = 105). Hepatic venous pressure gradient (HVPG) was measured at baseline, after intravenous propranolol, and 1 year after randomization to NSBBs (n = 52) or placebo (n = 53) (PREDESCI trial). miRNAs were analyzed at baseline and at 1 year.
RESULTS
RESULTS
Nineteen patients (18%) developed ascites, of whom 17 developed ascites after 1 year. miR-181b-5p levels at 1 year, but not at baseline, were higher in patients that developed ascites. The AUC of miR-181b-5p at 1 year to predict ascites was 0.7 (95% CI 0.59-0.78). miR-429 levels were lower at baseline in acute HVPG responders to NSBBs (AUC 0.65; 95% CI, 0.53-0.76), but levels at baseline and at 1 year were not associated with the HVPG response to NSBBs at 1 year.
CONCLUSIONS
CONCLUSIONS
Serum miR-181b-5p is a promising non-invasive biomarker to identify patients with compensated cirrhosis at risk of ascites development.
LAY SUMMARY
BACKGROUND
Ascites marks the transition from the compensated to decompensated stage in cirrhosis and indicates a worsening in prognosis. There are currently no easily accessible tools to identify patients with compensated cirrhosis at risk of developing ascites. We evaluated the levels of novel molecules termed microRNAs in the blood of patients with compensated cirrhosis and observed that miR-181b-5p can predict which patients are going to develop ascites.
Identifiants
pubmed: 34712934
doi: 10.1016/j.jhepr.2021.100368
pii: S2589-5559(21)00144-0
pmc: PMC8531668
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100368Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors have declared that no personal or financial competing interests exist. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
Sci Rep. 2020 Jan 9;10(1):100
pubmed: 31919459
Clin Gastroenterol Hepatol. 2020 Feb;18(2):313-327.e6
pubmed: 31176013
Circ Res. 2017 Jan 6;120(1):49-65
pubmed: 27756793
Hepatol Commun. 2020 Dec 02;5(2):309-322
pubmed: 33553977
PLoS One. 2013 Jun 21;8(6):e66577
pubmed: 23805240
World J Hepatol. 2017 Apr 28;9(12):586-594
pubmed: 28515844
J Hepatol. 2006 Jan;44(1):217-31
pubmed: 16298014
Am J Gastroenterol. 2012 Mar;107(3):418-27
pubmed: 22334252
Gastroenterology. 2007 Aug;133(2):481-8
pubmed: 17681169
JHEP Rep. 2021 Jan 19;3(2):100233
pubmed: 33665588
Lancet. 2019 Apr 20;393(10181):1597-1608
pubmed: 30910320
PLoS One. 2017 Mar 21;12(3):e0174108
pubmed: 28323879
Biometrics. 2000 Jun;56(2):337-44
pubmed: 10877287
J Cell Physiol. 2019 May;234(5):5451-5465
pubmed: 30471116
Cell Res. 2008 Oct;18(10):997-1006
pubmed: 18766170
Am J Gastroenterol. 2007 May;102(5):1116-26
pubmed: 17391317
Gastroenterology. 2006 Nov;131(5):1611-24
pubmed: 17101332
Dig Dis Sci. 2015 Aug;60(8):2346-52
pubmed: 25976622
Sci Rep. 2017 Oct 18;7(1):13514
pubmed: 29044172